Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

  • Technology appraisal guidance
  • TA394
  • Published: 
Download (PDF)

What has NICE said?

Evolocumab (Repatha) is recommended as a possible treatment for adults with primary hypercholesterolaemia or mixed dylipidaemia if:

  • the dose of evolocumab is 140 mg every 2 weeks and

  • the level of low‑density lipoprotein (LDL) cholesterol is not well controlled on the maximum recommended dose of cholesterol-lowering drugs or on the maximum dose that the person can tolerate.

What does this mean for me?

If you are not eligible for treatment as described above, you should be able to continue taking evolocumab until you and your doctor decide it is the right time to stop.

The condition and the treatment

Primary hypercholesterolaemia and mixed dyslipidaemia are medical terms meaning that a person's cholesterol levels are too high. High cholesterol can increase the risk of heart disease.

There are several types of cholesterol-lowering drugs that work in different ways. They include statins and ezetimibe.

Evolocumab is a drug that helps the liver to remove cholesterol from the blood. It is given by injection.

NHS Choices may be a good place to find out more.

This organisation can give you advice and support:

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-1947-5

  • Information Standard